Compounded infliximab (Ref: 2020/S 209-511772)


The framework agreement is for the provision of compounded infliximab. This entails suppliers sourcing the product from the manufacturer and compounding it, under aseptic conditions, into an appropriate infusion device and supplying to the trust ready for use by a clinician. The framework is split into three lots for the three available brands of infliximab; Inflectra, Remicade and Remsima respectively.

Start date


End date


Contract type

Framework Agreement

List of suppliers

Portsmouth, Quantum, ITH, Baxter, Qualasept Ltd (Bath ASU).

Contact name

Julia Asplin

Contact email

Contact number